ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States. Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. The company also develops a cryopreserved version of rilparencel that allows for long-term product preservation to be used in Phase 2 and 3 trials of rilparencel. ProKidney Corp. was founded in 2015 and is headquartered in Winston-Salem, North Carolina. Show more
Location: 2000 Frontis Plaza Blvd., Winston-Salem, NC, 27103, United States | Website: https://prokidney.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
1.812B
52 Wk Range
$0.46 - $7.13
Previous Close
$5.18
Open
$4.81
Volume
17,749,272
Day Range
$4.48 - $5.45
Enterprise Value
1.12B
Cash
328.5M
Avg Qtr Burn
-30.32M
Insider Ownership
30.05%
Institutional Own.
41.66%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Rilparencel (REACT®) Details Chronic kidney disease, Type 2 diabetes | Phase 3 Update | |
Rilparencel (REACT®) Details Chronic kidney disease, Type 2 diabetes | Phase 2 Update | |
Rilparencel (REACT®) Details Chronic kidney disease, Diabetes | Phase 2 Update | |
Rilparencel (REACT®) Details Chronic kidney disease, Type 2 diabetes | Failed Discontinued |